Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
About ONP-002
ONP-002 is a fully synthetic neurosteroid being developed to treat mTBI. In preclinical studies, the drug demonstrated equivalent or better neuroprotective effects compared with related neurosteroids. Animal models of concussion showed the drug reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety and motor/sensory performance. Additionally, ONP-002 is lipophilic and can cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation while restoring proper blood flow.
About Mild Traumatic Brain Injury (mTBI)
Concussions are an unmet medical need that affects millions worldwide. Repetitive concussions can increase the risk of developing chronic traumatic encephalopathy and other neuropsychiatric disorders. It is estimated that 5 million concussions occur in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207458097/en/
813-286-7900
jhuffman@oragenics.com
LHA Investor Relations
212-201-6614
tpatel@lhai.com
Source: